It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.


Corporate news

Evotec expands into gene therapy
Hamburg, Germany, April 6, 2020

Evotec SE today announced that the Company has established a dedicated site for research and development of gene therapy-based projects: Evotec Gene Therapy (“Evotec GT”) which will start operations with a strong team of gene therapy experts at an R&D site in Orth/Donau, Austria.

Evotec and Takeda enter into multi-year gene therapy research alliance
Hamburg, Germany, April 6, 2020

Evotec SE today announced that Evotec GT, with operations in Austria, has established a long-term research alliance with Takeda to support Takeda’s growing number of research stage gene therapy discovery programmes. Evotec GT is an integral part of Evotec’s integrated fully modality-agnostic drug discovery platform that combines all activities involved with the discovery, development, and manufacturing of therapeutics along the value chain. 

Evotec Statement on COVID-19
Hamburg, Germany, April 5, 2020

Many of you have been asking us about the Coronavirus and its potential impact on Evotec and its affiliates. At Evotec, we are actively managing our operations to maintain business continuity while taking measures to protect the health and wellbeing of our employees, their families and the local communities in which they live and work. We have taken a number of steps to ensure the continued health and safety of our colleagues during this challenging time.

Evotec expands its iPSC-based cell therapy platform EVOcells through licensing agreement with panCELLa
Hamburg, Germany, and Toronto, Canada, April 2, 2020

Evotec SE and the innovative biotechnology company panCELLa Inc. announced today that the companies have entered into a licensing and investment agreement. Under the terms of the agreement, Evotec will receive a non-exclusive licence to access panCELLa’s proprietary iPS cell lines “iACT Stealth Cells™”, which are genetically modified to prevent immune rejection of derived cell therapy products (“cloaking”). 

Evotec and Ildong to collaborate with development projects on INDiGO platform
Hamburg, Germany, March 31, 2020

Evotec SE announced today that the Company has entered into a strategic collaboration with Ildong Pharmaceutical Co., Ltd. (“Ildong”), a leading pharmaceutical company in South Korea, to accelerate the development of several of Ildong’s proprietary projects through access to Evotec’s INDiGO platform.

Evotec SE fiscal year 2019 results: : Excellent 2019 performance; very good outlook for continued growth 2020
Hamburg, Germany, March 26, 2020

Evotec SE today reported financial results and corporate updates for the fiscal year ended 31 December 2019. Group revenues up 19% to € 446.4 m, adjusted Group EBITDA up 29% to € 123.1 m, unpartnered R&D expenses of € 37.5 m, liquidity position more than doubled to € 320.0 m.

Evotec partner Forge enters into collaboration with Roche to develop novel antibiotic
San Diego, USA, March 25, 2020

Evotec’s partner Forge Therapeutics, Inc. (“Forge”) today announced a research collaboration and option agreement with Hoffmann-La Roche Ltd. (“Roche”) to license one of its novel antibiotics for the treatment of hospital-based lung infections. The targeted infections includes those cited on the CDC’s most urgent threats list, which commonly occur in people with weakened immune systems and chronic lung diseases.

Evotec SE to report fiscal year 2019 results on 26 March 2020
Hamburg, Germany, March 19, 2020

Evotec SE will report its financial results for 2019 on Thursday, 26 March 2020. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2020.

First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis
Hamburg, Germany, February 27, 2020

Today a consortium of philanthropic, non-profit and private sector organizations launched a collaboration that aims to accelerate the development of novel “pan-TB” drug regimens for the treatment of tuberculosis (TB) that are ready for phase 3 development. The regimens will be designed to have little to no drug resistance and an acceptable safety profile, and be better-tolerated, shorter in duration and simpler to use than existing options. Such regimens are intended to be a central component of efforts to address the current complexities and challenges of TB treatment.

Infographic: How to find effective endometriosis treatments
by Larissa Warneck, Labiotech, February 5, 2020

The exact number of women suffering from endometriosis is unknown. However, it is estimated that 10% of women worldwide are affected. Endometriosis is a debilitating disease in which the endometrial cells that usually line the uterus are found in other regions of the body.

Evotec and Bayer advance further programme into Phase I clinical development
Hamburg, Germany, January 30, 2020

Evotec SE announced today that its partner Bayer AG has decided to advance a further programme from the endometriosis multi-target alliance into clinical Phase I development.

Evotec and Indivumed announce second joint drug discovery programme
Hamburg, Germany, January 23, 2020

Evotec SE and Indivumed today announced that the companies have entered into a new research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer (“NSCLC”).

Just – Evotec Biologics announces product development and manufacturing agreement with OncoResponse
Hamburg, Germany, January 16, 2020

Evotec SE today announced that its wholly-owned Seattle-based subsidiary company Just – Evotec Biologics, Inc. has established a collaborative relationship with OncoResponse, Inc., a biotech company developing human antibodies as product candidates for multiple high value targets associated with immunosuppressive myeloid biology.

Just – Evotec Biologics initiates construction of first J.POD® facility in North America
Hamburg, Germany, January 14, 2020

Evotec SE today announced that the wholly-owned Seattle-based company Just – Evotec Biologics initiated the construction of a late-stage clinical and commercial manufacturing facility for biologics in Redmond, Washington.

Just – Evotec Biologics enters into multi-year collaboration with MSD around facility of the future
Hamburg, Germany, January 14, 2020

Evotec SE today announced that its wholly-owned Seattle-based subsidiary company Just – Evotec Biologics, Inc. has expanded its collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, regarding the development of innovative technologies for the production of biologics of the highest quality.

Bayer and Evotec form new strategic alliance focusing on polycystic ovary syndrome
Hamburg and Berlin, Germany, January 9, 2020

Evotec SE and Bayer AG today announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (“PCOS”).

Evotec and Bristol-Myers Squibb expand iPSC collaboration
Hamburg, Germany, January 7, 2020

Evotec SE announced today that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company following the decision to expand the collaboration to include additional cell lines.

Evotec to attend upcoming investor conferences
Hamburg, Germany, January 2, 2020

Evotec SE announced today that its management will be presenting at and attending investor conferences in January and February 2020.


Ad hoc releases

Please find below Evotec's most recent ad hoc releases according to Article 17 European Market Abuse Regulation (MAR).


Evotec SE: Increase of profitability guidance for financial year 2019
Hamburg, January 20, 2020

Evotec SE today announced an increase in its profitability guidance for the financial year 2019 after the preliminary completion of the latest evaluation of the Company's financial performance.


Other announcements


The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec SE, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Contact us

Gabriele Hansen

SVP, Corporate Communications, Marketing & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Anja Ben Lekhal

Investor Relations Associate

T + 49 40 56081 210 F +49 40 56081 222 vCard